延迟的氨酸皮肤冲洗反应确定了晚年抑郁症的认知障碍
Yan Chen1, You Wu2, Dandan Wang3
1Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Alzheimer's Disease and Related Disorders Center, Shanghai Jiao Tong University, Shanghai 200030, China.
Journal of affective disorders
|March 20, 2025
概括
延迟的尼亚皮肤冲洗反应 (NSFR) 可以识别晚年抑郁症 (LLD) 患者的认知障碍. 这种生物标志物还预测了LLD的未来认知衰退,提供了一种新的诊断方法.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 精神病学是一个精神病学.
背景情况:
- 晚年抑郁症 (LLD) 通常与认知障碍 (CI) 相关.
- 对LLD患者的CI的准确识别和预后对于有效的管理至关重要.
- 素皮肤冲洗反应 (NSFR) 已成为一种潜在的生理标记物.
研究的目的:
- 研究NSFR在具有或没有CI的LLD患者中的歧视性和预测价值.
- 探索NSFR作为一种潜在的生物标志物,用于识别LLD中的CI.
- 评估NSFR在LLD中预测认知轨迹的实用性.
主要方法:
- 该研究包括86名LLD患者 (46名具有CI,40名没有CI),22名阿尔茨海默病患者和32名健康对照.
- 用蒙特利尔认知评估 (MoCA) 评估认知功能.
- 使用修改的协议测量NSFR,并使用多变量ANOVA和ROC曲线分析数据.
主要成果:
- 在LLD患者中,NSFR与认知功能有显著的反相关性 (R = -0.456,P < .001).
- 在CI的LLD患者中,NSFR参数logEC50升高,显示AUC为0.767以区分CI.
- 基线logEC50预测了LLD患者的认知预后 (AUC = 0.826),与MoCA结合时预测得到改善.
结论:
- 延迟的NSFR是一种有前途的生物标志物,用于识别LLD患者的CI.
- NSFR可以预测认知轨迹,有助于对LLD中CI的预后评估.
- 这项研究引入了一种用于精确识别和预测LLD中CI的新方法.
相关概念视频
01:30Cognitive Development During Adulthood
38
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
38
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
87
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
87
01:27CNS Depressants: Alcohol and Nicotine
166
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
166
01:03Long-term Depression
2.5K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.5K
01:23Antidepressant Drugs: MAOIs and Other Agents
174
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
174
01:22Alzheimer's Disease: Treatment
139
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
139